Bloodstream-delivered cell therapy slows muscle decline in young people with Duchenne muscular dystrophy, trial finds

A compartment therapy called deramiocel could dilatory musculus weakening successful boys and young men with precocious Duchenne muscular dystrophy (DMD) and whitethorn besides dilatory bosom harm successful those who already person bosom musculus disease, a Phase III objective proceedings published successful The Lancet has found.